DK2575878T3 - Vacciner omfattende kolesterol og cpg som eneste adjuvans-bæremolekyler - Google Patents

Vacciner omfattende kolesterol og cpg som eneste adjuvans-bæremolekyler Download PDF

Info

Publication number
DK2575878T3
DK2575878T3 DK11727536.2T DK11727536T DK2575878T3 DK 2575878 T3 DK2575878 T3 DK 2575878T3 DK 11727536 T DK11727536 T DK 11727536T DK 2575878 T3 DK2575878 T3 DK 2575878T3
Authority
DK
Denmark
Prior art keywords
antigen
cpg
virus
vaccine
aspects
Prior art date
Application number
DK11727536.2T
Other languages
English (en)
Inventor
Heather Lynn Davis
Risini Dhammika Weeratna
Paul Joseph Dominowski
Original Assignee
Zoetis Belgium S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44626939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2575878(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Belgium S A filed Critical Zoetis Belgium S A
Application granted granted Critical
Publication of DK2575878T3 publication Critical patent/DK2575878T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Claims (11)

1. Vaccine omfattende et eller flere antigener og en adjuvans, hvor det ene eller de flere antigener hver uafhængigt er et mikrobielt antigen, et selvantigen, et tumorantigen, et allergen eller et vanedannende stof, og adjuvansen består af et eller flere isolerede CpG-oligonukleotider eller en TLR-agonist, som er et oligoribonukleotid, og kolesterol.
2. Vaccine ifølge krav 1, hvor det ene eller de flere antigener hver uafhængigt er et peptid, et peptid, der er konjugeret til et bærerprotein, et peptid, der er konjugeret til en viruslignende partikel, et polypeptid, et rekombinant protein, et oprenset protein, helt dræbt patogen, levende svækket virus eller virusvektor, der eksprimerer et antigen, levende svækkede bakterier eller en bakterievektor, der eksprimerer et antigen, et polysaccharid, et polysaccharid, der er konjugeret til et bærerprotein, et hapten, et hapten, der er konjugeret til et bærerprotein, eller et lille molekyle.
3. Vaccine ifølge krav 2, hvor antigenet er af bakteriel oprindelse, viral oprindelse eller parasitisk oprindelse.
4. Vaccine ifølge krav 3, hvor a) bakterieantigenet er hele dræbte bakterier, levende svækkede bakterier eller oprensede bakterieproteiner; eller b) virusantigenet er hel dræbt virus, levende svækket virus eller oprensede virusproteiner.
5. Vaccine ifølge krav 2, hvor bærerproteinet er et bakterielt toksoid eller derivat, Pseudomo/ias-eksotoxin, KLH eller en viruslignende partikel.
6. Vaccine ifølge krav 5, hvor a) det bakterielle toksoid er difteritoksoid eller et derivat deraf; eller b) den viruslignende partikel er HBsAg, HBcAg, E. co//-bakteriofag Οβ, Norwalk virus eller influenza HA.
7. Vaccine ifølge krav 1, hvor a) det vanedannende stof er nikotin eller et nikotinlignende molekyle; eller b) tumorantigenet er et eller flere blandt survivin, Her-2, EFGRvlll, PSA, PAP eller PMSA.
8. Vaccine ifølge krav 2, hvor haptenet, der er konjugeret til et bærerprotein, er nikotin eller et nikotinlignende molekyle, der er konjugeret til difteritoksoid eller et derivat deraf.
9. Vaccine ifølge krav 1, hvor mængden af kolesterol i forhold til mængden af antigen er 0,1 til 50 gange større efter vægt, 1 til 10 gange større efter vægt eller vægtmæssigt svarende til antigenet.
10. Vaccine ifølge krav 1, yderligere omfattende en farmaceutisk bærer.
11. Vaccine ifølge et hvilket som helst af kravene 1 til 10 til anvendelse i en fremgangsmåde til inducering af en antigen-specifik immunreaktion hos et individ med behov herfor, hvor vaccinen indgives i en mængde, der er virksom til at inducere en antigenspecifik immunreaktion hos individet.
DK11727536.2T 2010-05-28 2011-05-27 Vacciner omfattende kolesterol og cpg som eneste adjuvans-bæremolekyler DK2575878T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34924410P 2010-05-28 2010-05-28
PCT/IB2011/052347 WO2011148356A1 (en) 2010-05-28 2011-05-27 Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules

Publications (1)

Publication Number Publication Date
DK2575878T3 true DK2575878T3 (da) 2018-08-13

Family

ID=44626939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11727536.2T DK2575878T3 (da) 2010-05-28 2011-05-27 Vacciner omfattende kolesterol og cpg som eneste adjuvans-bæremolekyler

Country Status (22)

Country Link
US (1) US10456463B2 (da)
EP (1) EP2575878B1 (da)
JP (3) JP2011251963A (da)
KR (1) KR101528021B1 (da)
CN (1) CN103025351B (da)
AU (2) AU2011259718B2 (da)
BR (1) BR112012030337B1 (da)
CA (1) CA2800158C (da)
CL (1) CL2012003299A1 (da)
DK (1) DK2575878T3 (da)
ES (1) ES2683316T3 (da)
HR (1) HRP20181039T1 (da)
HU (1) HUE038894T2 (da)
LT (1) LT2575878T (da)
MX (1) MX347471B (da)
NZ (1) NZ603527A (da)
PL (1) PL2575878T3 (da)
PT (1) PT2575878T (da)
RS (1) RS57428B1 (da)
SI (1) SI2575878T1 (da)
WO (1) WO2011148356A1 (da)
ZA (1) ZA201208837B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2477753C2 (ru) 2008-12-09 2013-03-20 Коули Фармасьютикал Груп, Инк. Иммуностимулирующие олигонуклеотиды
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
BR112015028748A2 (pt) * 2013-05-14 2017-09-19 Zoetis Services Llc Composições de vacina compreendendo oligonucleotídeos imunoestimulantes
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
KR20200039025A (ko) * 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
US20160256540A1 (en) 2013-10-17 2016-09-08 Zoetis Services Llc Methods And Compositions For Treatment Of S. Equi Infection
CN105899199A (zh) * 2013-11-26 2016-08-24 硕腾服务有限责任公司 诱导免疫应答的组合物
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
HUE054422T2 (hu) * 2015-07-20 2021-09-28 Zoetis Services Llc Liposzómás adjuváns készítmények
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
KR20200060540A (ko) 2015-09-09 2020-05-29 칭화 유니버시티 고-효율 백신 아쥬반트로서 메발로네이트 경로 억제제
CN107149671B (zh) * 2016-03-03 2021-02-05 郭文江 一种药物组合物及其应用
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
CR20200260A (es) * 2017-12-15 2020-08-01 Bayer Animal Health Gmbh Composiciones inmunoestimulantes
CA3146842A1 (en) * 2019-07-12 2021-01-21 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CN115645417A (zh) * 2022-10-17 2023-01-31 武汉轻工大学 鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
MXPA02003059A (es) 1999-09-27 2002-09-30 Univ Iowa Res Found Metodos relacionados con interferon inducido por acido nucleico inmunoestabilizador.
CN1301572A (zh) * 1999-10-28 2001-07-04 上海生物制品研究所 用于疫苗的佐剂组合物
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
DE60229422D1 (de) 2001-08-17 2008-11-27 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
RU2322258C2 (ru) * 2001-11-07 2008-04-20 Цитос Байотекнолоджи Аг Антигенные матрицы для лечения заболевания костей
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
JP2006505523A (ja) * 2002-08-12 2006-02-16 ダイナバックス テクノロジーズ コーポレイション 免疫調節組成物、その製造方法および使用方法
JP2007516219A (ja) * 2003-05-07 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法
AU2004269379A1 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic HIV compositions and related methods
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
JP2008500963A (ja) * 2004-03-12 2008-01-17 イデラ ファーマシューティカルズ インコーポレイテッド 第二世代免疫調節性オリゴヌクレオチドを用いて増幅されたｈｉｖワクチン活性
EP1776105A2 (en) * 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
WO2006056142A1 (fr) * 2004-11-29 2006-06-01 Changchun Huapu Biotechnology Co., Ltd. Desoxynucleotides cpg a brin unique a utiliser comme adjuvant
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
JP5161770B2 (ja) * 2006-05-31 2013-03-13 東レ株式会社 免疫刺激オリゴヌクレオチド及びその医薬用途
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
AU2008252577A1 (en) * 2007-05-17 2008-11-27 Coley Pharmaceutical Gmbh Class A oligonucleotides with immunostimulatory potency
WO2009120247A2 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
AU2009263759B2 (en) 2008-06-27 2013-06-06 Zoetis Services Llc Novel adjuvant compositions

Also Published As

Publication number Publication date
JP2017048187A (ja) 2017-03-09
MX2012013731A (es) 2013-12-16
SI2575878T1 (sl) 2018-12-31
WO2011148356A1 (en) 2011-12-01
CA2800158C (en) 2020-07-21
US20130084306A1 (en) 2013-04-04
US10456463B2 (en) 2019-10-29
JP2011251963A (ja) 2011-12-15
BR112012030337B1 (pt) 2021-04-27
HUE038894T2 (hu) 2018-12-28
CL2012003299A1 (es) 2013-03-08
AU2011259718A1 (en) 2012-12-06
CA2800158A1 (en) 2011-12-01
KR101528021B1 (ko) 2015-06-10
HRP20181039T1 (hr) 2018-08-24
PT2575878T (pt) 2018-10-03
AU2016203611A1 (en) 2016-06-16
MX347471B (es) 2017-04-24
KR20130069668A (ko) 2013-06-26
LT2575878T (lt) 2018-11-12
ES2683316T3 (es) 2018-09-26
AU2011259718B2 (en) 2016-03-03
EP2575878A1 (en) 2013-04-10
PL2575878T3 (pl) 2018-12-31
BR112012030337A2 (pt) 2017-01-24
CN103025351A (zh) 2013-04-03
JP6034285B2 (ja) 2016-11-30
NZ603527A (en) 2014-10-31
EP2575878B1 (en) 2018-06-13
JP2013532140A (ja) 2013-08-15
RS57428B1 (sr) 2018-09-28
AU2016203611B2 (en) 2017-06-15
JP6133482B2 (ja) 2017-05-24
CN103025351B (zh) 2016-08-24
ZA201208837B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
DK2575878T3 (da) Vacciner omfattende kolesterol og cpg som eneste adjuvans-bæremolekyler
EP2376107B1 (en) Immunostimulatory oligonucleotides
US20060019916A1 (en) Immunostimulatory nucleic acids for inducing IL-10 responses
US8552165B2 (en) Immunostimulatory oligonucleotides